The recombinant fusion protein DTAT that targets uPAR and delivers the potent catalytic portion of DT has the advantage of simultaneously targeting both overexpressed uPAR on GBM cells and on tumor neovasculature [86,87]. This evidence concerns the gene PLAUR and glioblastoma.